Cargando…

SETBP1 Mutations Drive Leukemic Transformation in ASXL1-Mutated MDS

Mutations in ASXL1 are frequent in patients with myelodysplastic syndrome (MDS) and associated with adverse survival yet the molecular pathogenesis of ASXL1 mutations are not fully understood. Recently it has been found that deletion of Asxl1 or expression of C-terminal-truncating ASXL1 mutations (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Daichi, Kitaura, Jiro, Matsui, Hirotaka, Hou, Hsin-An, Chou, Wen-Chien, Nagamachi, Akiko, Kawabata, Kimihito Cojin, Togami, Katsuhiro, Nagase, Reina, Horikawa, Sayuri, Saika, Makoto, Micol, Jean-Baptiste, Hayashi, Yasutaka, Harada, Yuka, Harada, Hironori, Inaba, Toshiya, Tien, Hwei-Fang, Abdel-Wahab, Omar, Kitamura, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501574/ https://www.ncbi.nlm.nih.gov/pubmed/25306901 http://dx.doi.org/10.1038/leu.2014.301

Ejemplares similares

Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation
por: Nagase, Reina, et al.
Publicado: (2018)

ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation
por: Saika, Makoto, et al.
Publicado: (2018)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
por: Morita, Yasuyoshi, et al.
Publicado: (2022)

Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
por: Asada, Shuhei, et al.
Publicado: (2018)

The molecular basis of myeloid malignancies
por: KITAMURA, Toshio, et al.
Publicado: (2014)

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
por: Sallman, David A, et al.
Publicado: (2017)

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2016)

Somatic SETBP1 mutations in myeloid malignancies
por: Makishima, Hideki, et al.
Publicado: (2013)

Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1 in tumorgenesis
por: Wang, Hongdan, et al.
Publicado: (2023)

Novel SETBP1 mutation in a chinese family with intellectual disability
por: Wang, Le, et al.
Publicado: (2023)

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
por: Balasubramani, Anand, et al.
Publicado: (2015)

ASXL1/2 mutations and myeloid malignancies
por: Medina, Edward A., et al.
Publicado: (2022)

CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia
por: Cui, Yajuan, et al.
Publicado: (2014)

SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome
por: Linder, Katherine, et al.
Publicado: (2017)

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

ASXL1 mutations in Chinese patients with essential thrombocythemia
por: Nie, Yan-Bo, et al.
Publicado: (2018)

Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies
por: Acuna-Hidalgo, Rocio, et al.
Publicado: (2017)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

Role of ASXL1 mutation in impaired hematopoiesis and cellular senescence
por: Uni, Masahiro, et al.
Publicado: (2018)

RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia
por: Bera, Rabindranath, et al.
Publicado: (2019)

Identification of SETBP1 Mutations by Gene Panel Sequencing in Individuals With Intellectual Disability or With “Developmental and Epileptic Encephalopathy”
por: Leonardi, Emanuela, et al.
Publicado: (2020)

Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish
por: Fang, Xiao, et al.
Publicado: (2021)

Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network
por: Xia, Yu-Kun, et al.
Publicado: (2020)

The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model
por: Hsu, Yueh-Chwen, et al.
Publicado: (2017)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia
por: Hu, WangQiang, et al.
Publicado: (2015)

Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature
por: Wang, L., et al.
Publicado: (2015)

Pathological ASXL1 Mutations and Protein Variants Impair Neural Crest Development
por: Matheus, Friederike, et al.
Publicado: (2019)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group
por: Bresolin, Silvia, et al.
Publicado: (2016)

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing
por: Ferrer-Marín, Francisca, et al.
Publicado: (2013)

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
por: Gelsi-Boyer, Véronique, et al.
Publicado: (2012)

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Acute myeloid leukemia in a father and son with a germline mutation of ASXL1
por: Seiter, Karen, et al.
Publicado: (2018)

Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia
por: Kim, Hyun-Young, et al.
Publicado: (2018)

ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells
por: Inoue, Daichi, et al.
Publicado: (2018)

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine
por: Rahmani, Nora E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h44r0rdgdrnbecf5fti4il7gl4